What oral medication can be used to treat chorea?

Oral Medications for Chorea

Dopamine antagonists, particularly haloperidol, are the first-line oral medications for symptomatic treatment of chorea, with VMAT2 inhibitors (tetrabenazine, deutetrabenazine, valbenazine) serving as FDA-approved alternatives specifically for Huntington's disease-related chorea. 1

Primary Treatment Options

Dopamine Antagonists (First-Line)

• Haloperidol is the most commonly recommended dopamine antagonist for chorea management, typically dosed at 0.5-2 mg every 4-6 hours orally 2
• Alternative dopamine antagonists include chlorpromazine (25-50 mg orally three to four times daily), though this carries significant QTc prolongation risk and requires cardiac monitoring 2
• These agents work by blocking dopamine receptors, directly addressing the pathophysiology of choreiform movements 1

VMAT2 Inhibitors (FDA-Approved for Huntington's Disease)

Tetrabenazine remains the original FDA-approved agent, dosed up to 100 mg/day, with demonstrated efficacy in reducing UHDRS total maximum chorea scores by 5 points versus 1.5 points for placebo 3

Deutetrabenazine offers improved tolerability compared to tetrabenazine, with dosing typically between 24-48 mg/day for most patients achieving ≥30% improvement in chorea scores 4

• Higher doses (>48 mg/day) can be used safely when needed for adequate chorea control, with no incremental safety concerns compared to lower doses 4
• This agent demonstrates favorable tolerability with fewer complications than tetrabenazine 5

Valbenazine provides the most selective VMAT2 inhibition, avoiding VMAT1-related side effects and potentially resulting in less parkinsonism, behavioral changes, and akathisia 6

• Demonstrates effectiveness in addressing chorea with broader benefits on functional outcomes 5
• Cost may be a significant barrier to access despite insurance coverage 6

Alternative Oral Agents

Anticonvulsants

Carbamazepine (4-10 mg/kg daily) has demonstrated efficacy specifically for rheumatic chorea, with improvement evident within 2-14 days at plasma levels of 2.8-8.2 μg/mL 7

• This is well below the typical antiepileptic therapeutic range of 8-12 μg/mL 7
• Particularly useful when chorea is associated with systemic lupus erythematosus or antiphospholipid antibody syndrome 1

Immunosuppressive Therapy Considerations

For chorea associated with SLE or antiphospholipid syndrome, glucocorticoids combined with immunosuppressive agents (azathioprine, cyclophosphamide) may be used to control underlying disease activity 1

• Antiplatelet and/or anticoagulation therapy should be administered in antiphospholipid-positive patients 1

Critical Safety Considerations

Cardiac monitoring is essential when using chlorpromazine due to significant QTc prolongation risk; avoid combining with other QT-prolonging medications 2

Elderly patients require dose reduction, starting with 12.5-25 mg for chlorpromazine due to increased sensitivity to anticholinergic effects, sedation, and extrapyramidal symptoms 2

VMAT2 inhibitors carry risk of depression, suicidality, and parkinsonism; careful monitoring for neuropsychiatric symptoms is required during treatment 5, 6

Treatment Selection Algorithm

1. For Huntington's disease-related chorea: Start with VMAT2 inhibitors (deutetrabenazine preferred for tolerability, valbenazine for selectivity) 5, 6
2. For non-HD chorea or when VMAT2 inhibitors unavailable: Use haloperidol 0.5-2 mg every 4-6 hours 2
3. For rheumatic chorea: Consider carbamazepine 4-10 mg/kg daily as first-line 7
4. For SLE-associated chorea: Combine dopamine antagonists with immunosuppressive therapy and anticoagulation if antiphospholipid antibodies present 1